Publications by authors named "E J Meinard G Moral"
Article Synopsis
- A comprehensive understanding of the healthcare system and neurology departments is essential for effectively implementing anti-amyloid antibody treatments in hospitals, especially regarding the organization and patient care.* -
- A survey of department heads from 16 Spanish hospitals showed consensus on the need for structural changes, such as focusing Alzheimer’s patients in specialized dementia units and expanding neurology services by hiring more staff and enhancing diagnostic procedures.* -
- The findings underscore the necessity for significant transformations in Spanish neurology departments to ensure the successful integration of anti-amyloid antibodies and promote fair access to new therapies for patients.*
The XVI Post-ECTRIMS meeting was held in Seville on 20 and 21 October 2023, where expert neurologists in multiple sclerosis (MS) summarised the main new developments presented at the ECTRIMS 2023 congress, which took place in Milan from 11 to 13 October. The aim of this article is to summarise the content presented at the Post-ECTRIMS Meeting, in an article in two parts. This second part covers the health of women and elderly MS patients, new trends in the treatment of cognitive impairment, focusing particularly on meditation, neuroeducation and cognitive rehabilitation, and introduces the concept of fatigability, which has been used to a limited extent in MS.
View Article and Find Full Text PDFThe XVI Post-ECTRIMS meeting took place in Seville on 20 and 21 October 2023. This meeting was attended by neurologists specialising in multiple sclerosis (MS) from Spain, who shared a summary of the most interesting innovations at the ECTRIMS congress, which had taken place in Milan the previous week. The aim of this article is to summarise new developments related to the pathogenesis, diagnosis and prognosis of MS.
View Article and Find Full Text PDFBackground: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients enrolled in the EMCOVID database. The DMTs were used to manage MS by reducing relapses, lesion accumulation, and disability progression.
View Article and Find Full Text PDF